The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells

@article{Smits2009TheTR,
  title={The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells},
  author={Evelien L. J. M. Smits and Nathalie Cools and Eva Lion and Kirsten Van Camp and Peter Ponsaerts and Zwi Nisan Berneman and Viggo F. I. Van Tendeloo},
  journal={Cancer Immunology, Immunotherapy},
  year={2009},
  volume={59},
  pages={35-46}
}
Immunotherapy for leukemia is a promising targeted strategy to eradicate residual leukemic cells after standard therapy, in order to prevent relapse and to prolong the survival of leukemia patients. However, effective anti-leukemia immune responses are hampered by the weak immunogenicity of leukemic cells. Therefore, much effort is made to identify agents that could increase the immunogenicity of leukemic cells and activate the immune system. Synthetic agonists of Toll-like receptor (TLR)7 and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 59 references

Similar Papers

Loading similar papers…